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S U M M A R Y
Ebola virus disease (EVD) is an understudied infection and many aspects of viral transmission and
clinical course remain unclear. With over 17 000 EVD survivors in West Africa, the World Health
Organization has focused its strategy on managing survivors and the risk of re-emergence of outbreaks
posed by persistence of the virus during convalescence. Sexual transmission from survivors has also been
documented following the 2014 epidemic and there are documented cases of survivors readmitted to
hospital with ‘recurrence’ of EVD symptoms. In addition to persistence of virus in survivors, there is also
some evidence for ‘reinfection’ with Ebola virus. In this paper, the evidence for recurrence and
reinfection of EVD and implications for epidemic control are reviewed.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Ebola virus disease (EVD) is an understudied infection, with
uncertainty around many aspects of transmission and disease.1,2
Acute infection is characterized by overwhelming viremia and
immune evasion.3 Direct contact with blood and body ﬂuids is the
dominant mode of transmission, but evidence is increasing that
other modes, including blood-borne, vertical, sexual, and aerosol
transmission, are possible. Ebola virus can cause symptoms in
clinically recovered patients despite clearance of virus from the
blood.4,5 With over 17 000 EVD survivors in West Africa, the World
Health Organization (WHO) has focused its strategy on managing
survivors and the risk of re-emergence of outbreaks posed by
chronic persistence of the virus.6 In addition to chronic persistence
of virus in survivors, there is also some evidence for reinfection.7,8
‘Recurrence’ or recrudescence refers to the reappearance of
symptoms in survivors due to the persistence of virus at
immunologically protected body sites, while ‘reinfection’ refers
to survivors being susceptible to acquiring new infections after
recovery. Both of these phenomena create a risk of emergence of
Ebola virus outbreaks and are a challenge to disease control efforts.* Corresponding author. Tel.: +61 2 9385 3811; fax: +61 2 9313 6185.
E-mail address: r.macintyre@unsw.edu.au (C.R. MacIntyre).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).There is much we do not yet understand about Ebola virus, and it
is timely to review the implications of recurrence and reinfection
for epidemic control.
2. Recurrence of Ebola virus
Ebola virus may persist at immunologically protected sites in
the body, including semen, vaginal ﬂuids, sweat, aqueous humour,
urine, and breast milk.4,9–13 A study of 93 survivors showed that
100% had Ebola virus RNA in the semen at 2–3 months post onset of
EVD, decreasing to 65% at 4–6 months and 26% at 7–9 months.13 A
positive PCR test may or may not indicate the presence of viable
virus. Only a positive virus culture conﬁrms infectious potential.
During the outbreak in Kikwit, Democratic Republic of the Congo in
1995, in addition to positive PCR for urine, semen, conjunctiva,
sweat, vaginal, and rectal samples from recovered patients, one
patient had live virus isolated from seminal ﬂuid up to 82 days
after disease onset.9 In another case, PCR was positive in sweat and
urine up to day 40. The last urine culture was positive for Ebola at
day 26 after onset, while sweat cultures were negative.12
The persistence of virus poses three risks: transmission to
others while asymptomatic (e.g., sexual transmission), reactivation
of illness (risk to the affected individual), and transmission to
others from symptomatic individuals with recrudescent illnessciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Animal studies support the persistence of Ebola virus at some sites
and the subsequent re-emergence of symptoms.14,15 However in
most animal studies, especially non-human primate studies, the
animals have tended to be sacriﬁced early; when this has not been
the case, the animals have not always been followed up for long
enough periods to be analogous to the time course of recrudescent
illness described in humans.
During the 2014 outbreak, a 43-year-old US physician
developed uveitis 9 weeks after clinical recovery and Ebola virus
was isolated from the aqueous humour.4 Whilst uveitis and ocular
complications had been described previously, this was the ﬁrst
time viable virus had been demonstrated to persist in the eye. In
past outbreaks, uveitis during convalescence was thought to be a
delayed immunological phenomenon, but recent evidence has
shown that reactivation of the virus can cause these symptoms.
Uveitis in survivors may be due to one or both of these factors and
needs further study.
More recently, neurological symptoms reappeared 9 months
after recovery in a nurse who survived EVD.5 She developed
meningitis and Ebola virus was detected in blood and cerebrospi-
nal ﬂuid (CSF). She was treated with an experimental drug that had
been used successfully to treat severe infection in primates.16
Whilst similar syndromes had been described in past outbreaks,
this was the ﬁrst time viable virus had been isolated in the CSF. In a
30-year-old woman in Sierra Leone, Ebola virus was detected
through RT-PCR at day 41 in CSF and at day 44 in sweat, while
blood and urine tests were negative.17 Studies of women who
acquired the infection during pregnancy have indicated that while
the woman may recover and clear the virus from blood, a high viral
load persists in amniotic ﬂuid, placenta, and foetus.18 The delivery
of recovered women, therefore, should be done with full infection
control precautions.
There is a lack of data in relation to the transmission of Ebola
through the body ﬂuids of recovered Ebola patients. Rowe et al.
examined the transmission of infection from convalescent patients
(who had recovered from the acute phase) to household members
and did not ﬁnd direct evidence of transmission.10 Five household
members had serological evidence of Ebola infection and one was
possibly due to sexual transmission after recovery.10 To date, only
one conﬁrmed case of EVD has been documented due to
transmission through the body ﬂuid of clinically well Ebola
survivors. During the 2014 West African outbreak, a 44-year-old
Liberian woman acquired Ebola virus from a recovered Ebola
survivor who was positive for Ebola virus by RT-PCR in semen at
199 days after recovery; the Ebola virus strain was genetically
matched with that of the case patient.19 The genetic sequencing of
virus in this couple has provided strong evidence of sexual
transmission of Ebola virus.20
3. Reinfection with Ebola virus
Anecdotal reports have raised questions around the possibility
of reinfection with Ebola virus, however a conﬁrmed case of
reinfection has never been reported.21,22 The ﬁrst potential case of
reinfection was reported by an aid worker, but was not conﬁrmed.7
In this instance, it was thought that lowered immunity in a
recovered patient may have contributed to reinfection after
exposure to a new Ebola patient.7 In another report, virus was
detected through PCR in two children aged <5 years in Monrovia
who had recovered clinically and had negative PCR results at the
time of discharge.8 Whether this was recrudescence or reinfection
is unclear.
Recovery from EVD requires both humoral and cell-mediated
immunity, and variability in the immune response has been
described between individuals and between outbreaks.23 Animalstudies also suggest that variability in host immunity can
determine whether the host can become susceptible to reinfection.
Conditions of partial immunity can lead to the reinfection of
recovered mice, which have been shown to develop lethal infection
after re-challenge with the virus.15 In the trial of ZMAb in
macaques, a second challenge with Ebola virus was done to test
reinfection.24 Viremia was demonstrated after re-challenge, and
two of 12 monkeys that had lower immunity succumbed to a re-
challenge. This shows that there is variability in individual host
immune responses and that in some cases a ﬁrst infection does not
protect from a second. The converse of this is that some people,
presumably with a more robust immune system, are thought to
develop subclinical or asymptomatic infection.25,26 According to a
recent report, a group of women in Guinea were not infected
despite repeated exposure to the virus, and only one of them had
Ebola virus antibodies in the blood.27 All of this points to great
variability in individual host susceptibility to infection and
reinfection based on innate immunity, as well as the viral load
to which the individual is exposed during a challenge or re-
challenge.
Reinfection is theoretically possible due to waning or partial
immunity, a high viral load during a re-challenge, or a combination
of both of these factors. Studies have shown that Ebola virus
antibodies wane after a few years in some survivors.28 The
antibody level required for optimal protection or immune memory
is not known, but cell-mediated immunity is also thought to play a
role.23 Figure 1 shows the possible outcomes for an EVD survivor
and the pathways through which a new outbreak could occur.
4. Discussion
The 2014 West African epidemic is the largest in history,
resulting in more than 28 000 cases and 11 000 deaths.29With over
17 000 survivors in West Africa, the magnitude and long-term
implications of recurrence and reinfection are unknown. If more
than one in four male EVD survivors has virus in the semen at 7–9
months,13 further cases are likely through sexual transmission. In
fact, at least two cases have been documented.10,19
Detailed studies of persistence in the vaginal ﬂuid of female
survivors have not been reported to date, but the available data
suggest that this is an additional risk.9 In terms of reinfection or
recrudescence, variability in host immunity and waning immunity
might be important. It is commonly said that healthcare worker
EVD survivors are immune and can safely go back into the ﬁeld to
treat EVD patients again, and may not even need personal
protective equipment.30 Some have even claimed that survivors
have ‘super powers’.30 This is clearly not the case, with increasing
case reports of recrudescence of disease in survivors.31 In addition,
the possibility of reinfection exists and is a function of host
immunity as well as the viral load to which an individual is
exposed. It may be possible that individuals who clear the virus
completely may be susceptible to reinfection under conditions of
waning or lowered immunity and a high viral load on re-challenge.
However, immunological conditions (e.g., arthralgia/arthritis) may
not easily be differentiated from symptoms of virus reactivation –
especially when it comes to treatment. Therefore, symptoms in
survivors require thorough evaluation, where possible, to identify
underlying infectious and non-infectious causes.
Whilst there remains uncertainty about the long-term sequelae
of EVD, a range of precautions can be taken to minimize the risk of
new cases and outbreaks in the context of a large number of
survivors in West Africa. Firstly, the use of condoms for sexual
contact should be promoted for survivors for at least 12 months,
until further research is available to determine the possible
duration of persistence in vaginal and seminal ﬂuid. Past outbreaks
indicate the presence of viral RNA in vaginal ﬂuids,9 and this needs
Figure 1. Possible outcomes for Ebola virus disease survivors.
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Although the WHO recommends testing survivors who have
positive semen on a regular basis until the virus is cleared,
recommendations are ambiguous for other body ﬂuids.32 The
clinical care and follow-up of survivors should focus on preventive
health (including vaccinations for vaccine-preventable diseases),
the management of chronic conditions and comorbidities, and
nutrition, to ensure optimal health and well-being. Ageing is
associated with immunosenescence and a predictable failing of
immunity.33 Therefore there may be an increased risk of
recrudescence of Ebola virus in ageing survivors over the longer
term, in much the same way as the risk of herpes zoster or
tuberculosis increases with age.33 This is correlated with an
exponential decline in immune function after the age of 50 years,34
and may pose a long-term risk for West Africa with its large
population of EVD survivors. Finally, surveillance and rapid
diagnostic and response capacity should be improved in high-
risk countries for the rapid detection and control of new outbreaks.
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